Heart Failure – The 2026 Evidence Update

Since the release of the 2021 ESC guidelines and the 2022 AHA/ACC/HFSA guidelines, research on heart failure has reached a remarkable level of intensity. Nonsteroidal mineralocorticoid receptor antagonists and incretin-based therapies have been introduced for the long-standing, treatment-resistant heart failure with mildly reduced or preserved ejection fraction, rapid in-hospital optimization of guideline-based therapy has become established in acute heart failure, digitalis glycosides have been reevaluated, and interventional valve therapy has expanded from the mitral valve to the tricuspid valve.